Webinar

FAPI-PET imaging & theranostics: A new era in targeting cancer and fibrotic diseases

While traditional imaging methods like FDG-PET are effective for detecting highly metabolic cancer cells, they fall short in specifically imaging the tumor microenvironment. Fibroblast Activation Protein (FAP)-targeted PET imaging addresses this by specifically visualizing the tumor stroma, which is richly populated with cancer-associated fibroblasts. This targeted approach introduces a new dimension in tumor evaluation, with applicability across a wide range of cancers.

Moreover, the high expression of FAP in fibrotic diseases further highlights its broad utility as a biomarker across diverse pathological conditions. FAP inhibitors (FAPI) enable non-invasive imaging of FAP, providing enhanced diagnostic precision while unlocking theranostic potential in both oncology and fibrotic disease applications.

 

Cancerous tumor cells close-up
divider

Panelist

Moderator: Paulo Rosado de Castro MD, PhD

Medical Director at Perceptive

John Babich, PhD

Co-founder, President, and CSO, Ratio Therapeutics

Jeremie Calais, MD, PhD

Associate Professor, Department of Molecular and Medical Pharmacology; Director, Theranostics Program, David Geffen School of Medicine at UCLA

Ken Herrmann, MD

Professor of Nuclear Medicine, Universitätsmedizin Essen, Universität Duisburg-Essen, Germany

Sherly Mosessian, PhD

Chief Scientific Officer, SOFIE

In this roundtable discussion, the panelists will:

  • Explore the dual utility of FAP as a biomarker for assessing treatment responses in oncology and fibrotic diseases
  • Review the advantages of FAP-targeted imaging and complementarity with FDG-PET
  • Discuss the theranostic applications of FAPI